Similarly, Arnould et al (2006) showed that breast cancer patients who responded well to neoadjuvant trastuzumab and docetaxel had an increased tumour infiltration with lymphocytes, NK cells, and cytotoxic proteins such as granzyme B than patients who had a poor response. The gene discussed is GZMB; the disease is neoplasm.